Aligos Therapeutics to Announce Phase 2a HERALD Study Results for ALG-055009 on September 19, 2024

Aligos Therapeutics, Inc., based in South San Francisco, announced it will disclose the primary outcomes from its Phase 2a HERALD study of ALG-055009. This thyroid hormone receptor beta (THR-β) agonist is being tested in patients with metabolic-dysfunction associated steatohepatitis (MASH). The announcement is scheduled for Thursday, September 19, 2024, prior to market opening. A conference call and webcast will follow at 8:30am ET/5:30am PT.

The company has organized a conference call and webcast, including a presentation, to discuss these results. Participants can join the live webcast through the Presentations & Events page on Aligos' website. Registration is recommended ten minutes before the start. A replay of the webcast will be accessible on the company’s website for 90 days post-event.

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to improving patient care through advanced therapies targeting liver and viral diseases. Their focus includes developing treatments for MASH and addressing viruses with significant unmet needs, such as hepatitis B and coronaviruses. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!